卵巢癌术前新辅助化疗筛选与评估的展望

doi:10.11904/j.issn.1002-3070.2014.06.015

Abstract

Abstract:

Ovarian cancer is the highest death rate of gynecologic malignant tumor.Currently,people recognize standard treatment for ovarian cancer was that reduction-Tumor cells of platinum based chemotherapy after surgery.But for those patients who have developed into advanced cancer that cannot be operated the surgeries directly,the application of preoperative Neoadjuvant chemotherapy(NACT)does have the superiority.which is recognized by the majority of clinical doctors,and has been widely used in the treatment of advanced malignant tumor.It is worthy to discussing which part of patients should choose the initial treatment of Neoadjuvant chemotherapy,rather than a direct treatment of destroying tumor cells.This article is summarizing the empirical cases based on related research,in order to help clinicians to make a decision on the treatment of ovarian cancer.

Key words: Advanced ovarian cancer, Neoadjuvant chemotherapy, Assessment, Screening criteria

CLC Number:

R730.53

SONG Yulin,WANG Jing. The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 553-556.

References

1 Stuart GCE,Kitchener H,Bacon M,et al.2010 Gynecologic Cancer Inter Group(GCIG)consensus statement on clinical trials in ovarian cancer.Report from the fourth ovarian cancer consensus conference[J].Gynecol Cancer,2011,21(3):750-755.
2 Vergote I,Trope CG,Amant F,et al.Neoadjuvant chemotherapy or primary surgery in stage IIIc-IV ovarian cancer[J].New Engl Med,2010,363(9):943-953.
3 Vergot IB,De Wever I,Decloedt J,et al.Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer[J].Semin Oncol,2000,27(1):31-36.
4 Hou JY,Kelly MG,Yu H,et al.neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease[J].Gynecologic Oncology,2007,105(1);211-217.
5 Petria L,Hogdall E,Christensen IJ,et al.Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer[J].APUIS,2006,114(5):359-363.
6 Brockbank EC,Ind TE,Barton DP,et al.Preoperative predictors of suboptimal primary surgical cytoreduction in patients with advanced ovarian carcinoma[J].Int J Gynecol Cancer,2004,14(1):42-50.
7 祝绚,甘晓琴,陈曼,等.血清肿瘤标志物检测在盆腔良恶性妇科肿瘤诊断与鉴别诊断中的意义[J].检验医学与临床,2013,10(17):2231-2232.
8 沈伟春.联检CA125、CA153、AFP和CEA在卵巢癌中的诊断价值[J].现代诊断与治疗,2013,24(14):3620-3621.
9 朱强,吉川裕幸,藤田信行,等.CT和核磁成像在原发性卵巢癌分期中的应用[J].中华肿瘤杂志,1999,21(4):296-299.
10 Dowdy SC,Mullany SA,Brandt KR,et al.The utility of computed to mography seans in predicting suboptimal cytoreductive surgery in women with adwanced ovarian carcinoma[J].Cancer,2004,101(2):346-352.
11 Qayyum A,Coakley FV,Westphalen AC,et al.Role of CT and MRI imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer[J].Gynecol Oncol,2005,96(2):301-306.
12 顾欣,娄阁,张嘉文,等.¹⁸FDG-PET诊断卵巢癌治疗后复发的价值[J].实用肿瘤学杂志,2007,21(3):270-272.
13 吴明秀.PET-CT在妇科恶性肿瘤的应用[J].中国医疗前沿,2013,8(6):87-88.
14 朱剑锋,邱刚,朱静红,等.PET-CT在诊断卵巢癌中的应用价值[J].中国医药指南,2013,11(21):194-195.
15 Fagotti A,Fanfani F,Ludovisi M,et al.Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer:a pilot study[J].Gynecol Oncol,2005,96(3):729-735.
16 Chi DS,Mus AF,Dao F,et al.An analysis of patients with bulky advanced stage ovarian,tubal,and peritoneal carcinoma treated with primary debulking surgery(PDS)during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy(NACT)[J].Gynecol Oncol,2012,124(1):10-14.
17 黄琳娟,孔北华,何丽.晚期卵巢癌新辅助化疗的Meta分析[J].现代妇产科进展,2013,22(1):28-31.

[1]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[2]	CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.
[3]	DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.
[4]	BA Zhichang, WANG Xinxin, CUI Wanhui, GUO Fei, ZHANG Xiushi. Value of diffusion weighted magnetic resonance imaging in the monitoring of neoadjuvant chemotherapy efficacy for uterine cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 518-522.
[5]	LI Jiaqi,LUO Hongyu,LUAN Jinwei,LI Yang,LI Xianglan. The progress of cancer malnutrition research during radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 93-96.
[6]	ZHU Hong,ZHU Li,HAN Shiyu,FANG Fang,YU Yang. The predictive value of DWI for progression free survival in patients with cervix cancer after neoadjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 519-523.
[7]	NING Siqing,ZHAN Botao,XU haisheng. The investigation of effects of TNP in the head and neck squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 540-544.
[8]	GENG Shumei,ZHAO Suyan,ZHANG Xiaowei,MA Xudong,DONG Jing,JIA Xihua. A clinical value of detecting vascular endothelial growth factor in ascites of advanced ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(5): 443-448.
[9]	MA Rong,CHEN Xihai,GENG Xiaoxing,LIU Shuang,ZHANG Heng. The evaluation of effectiveness of concurrent chemoradiation for locally advanced cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 314-318.
[10]	TENG Chong,SONG Xiaowei,CAI Li. Effect and clinical significance of Ki-67 in neoadjuvant chemotherapy for breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(2): 188-192.
[11]	YIN Mingzhu,LOU Ge,CHEN Xiuwei,GU Taihua. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(1): 40-45.
[12]	WU Liangzhi, JIANG Nan, ZHANG Yi. Study on the molecule mechanisms efficacy of two kinds of neoadjuvant chemotherapy in locally and advanced cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(5): 427-429.
[13]	XU Ye, GAO Ying, LOU Ge. A clinical observation on neoadjuvant chemotherapy for ovary tumor of advanced stage treated with paclitaxel liposome and nedaplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2008, 22(6): 512-513.

The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments